Home » Drug Information
Recently Approved Drugs
The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. The database is searchable by year or by medical area. Drug information typically includes the drug name, approval status, indication of use, and clinical trial results.
Find out more about the types of drugs included in this listing.
Year: 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | [2003] | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | View By Medical Area
Crestor (rosuvastatin calcium); AstraZeneca;
For the treatment of primary hypercholesterolemia (heterozygous
familial and nonfamilial) and mixed dyslipidemia, Approved August 2003
Levitra (vardenafil); Bayer, GlaxoSmithKline;
For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003
Amevive (alefacept); Biogen;
For moderate to severe chronic plaque psoriasis., Approved January 2003
Finacea (azelaic acid) Gel, 15%; Berlex Laboratories;
Gel formulation for the treatment of rosacea., January 2003
Aldurazyme (laronidase); Genzyme;
For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65, Approved May 2003
Fabrazyme (agalsidase beta); Genzyme;
For the treatment of Fabry disease in adult patients, Approved April 2003
Somavert (pegvisomant); Pharmacia;
Injectable formulation for the treatment of acromegaly, Approved March 2003
Aloxi (palonosetron); MGI Pharma, Helsinn Healthcare;
For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, Approved August 2003
Emend (aprepitant); Merck;
For the treatment of nausea and vomiting associated with chemotherapy, Approved March 2003
Oxytrol (oxybutynin transdermal system); Watson Pharmaceuticals;
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency., Approved March 2003
Bexxar; Corixa;
For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse, Approved June 2003
Levitra (vardenafil); Bayer, GlaxoSmithKline;
For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003
Reyataz (atazanavir sulfate); Bristol-Myers Squibb;
For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved July 2003
Zemaira (alpha1-proteinase inhibitor); Aventis Behring;
For the treatment of alpha1-proteinase inhibitor deficiency (Alpha-1) and emphysema, Approved July 2003
Amevive (alefacept); Biogen;
For moderate to severe chronic plaque psoriasis., Approved January 2003
FluMist ( Influenza Virus Vaccine); MedImmune;
For the prevention of disease caused by influenza A and B viruses, Approved June 2003
Fuzeon (enfuvirtide); Trimeris, Roche;
For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved March 2003
Lexiva (fosamprenavir calcium); GlaxoSmithKline;
For the treatment of HIV infection in adults in combination with other antiretroviral agents., Approved October 2003
Reyataz (atazanavir sulfate); Bristol-Myers Squibb;
For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved July 2003
Aldurazyme (laronidase); Genzyme;
For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65, Approved May 2003
Somavert (pegvisomant); Pharmacia;
Injectable formulation for the treatment of acromegaly, Approved March 2003
Velcade (bortezomib); Millennium Pharmaceuticals;
Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies., Approved May 2003
Fabrazyme (agalsidase beta); Genzyme;
For the treatment of Fabry disease in adult patients, Approved April 2003
Oxytrol (oxybutynin transdermal system); Watson Pharmaceuticals;
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency., Approved March 2003
UroXatral (alfuzosin HCl extended-release tablets); Sanofi-Synthelabo;
For the treatment of of the signs and symptoms of benign prostatic hyperplasia, Approved June 2003
Cialis (tadalafil); Eli Lilly;
Oral agent for the treatment for erectile dysfunction, Approved December 2003
Levitra (vardenafil); Bayer, GlaxoSmithKline;
For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003
Namenda (memantine HCl); Forest Laboratories;
For the treatment of moderate to severe dementia of the Alzheimer’s type., Approved October 2003
Aloxi (palonosetron); MGI Pharma, Helsinn Healthcare;
For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, Approved August 2003
Bexxar; Corixa;
For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse, Approved June 2003
Emend (aprepitant); Merck;
For the treatment of nausea and vomiting associated with chemotherapy, Approved March 2003
Iressa (gefitinib); AstraZeneca;
For the second-line treatment of non-small-cell lung cancer, Approved May 2003
Plenaxis (abarelix for injectable suspension); Praecis Pharmaceuticals;
For treatment of advanced prostate cancer, Approved December 2003
UroXatral (alfuzosin HCl extended-release tablets); Sanofi-Synthelabo;
For the treatment of of the signs and symptoms of benign prostatic hyperplasia, Approved June 2003
Velcade (bortezomib); Millennium Pharmaceuticals;
Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies., Approved May 2003
Aldurazyme (laronidase); Genzyme;
For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65, Approved May 2003
Aldurazyme (laronidase); Genzyme;
For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65, Approved May 2003
Iressa (gefitinib); AstraZeneca;
For the second-line treatment of non-small-cell lung cancer, Approved May 2003
Zemaira (alpha1-proteinase inhibitor); Aventis Behring;
For the treatment of alpha1-proteinase inhibitor deficiency (Alpha-1) and emphysema, Approved July 2003
